| Dr William Joshua Guffey, PHARMD | |
|
University Of Georgia, College Of Pharmacy, Athens, GA 30602-0002 | |
| (706) 542-7230 | |
| (706) 542-5228 |
| Full Name | Dr William Joshua Guffey |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | University Of Georgia, Athens, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013105147 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH023732 (Georgia) | Primary |
| 183500000X | Pharmacist | 11812 (South Carolina) | Secondary |
| 183500000X | Pharmacist | 18937 (North Carolina) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Joshua Guffey, PHARMD University Of Georgia, College Of Pharmacy, Athens, GA 30602-0002 Ph: () - | Dr William Joshua Guffey, PHARMD University Of Georgia, College Of Pharmacy, Athens, GA 30602-0002 Ph: (706) 542-7230 |
News Archive
A new study shows how employers are cost-shifting. And Democratic politicians are pointing fingers for Obamacare's website woes.
When it comes to the examination room at your health care clinic, you might think that avoiding catching the flu or other more deadly viruses is out of your hands, so to speak.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million.
Bernhard Schwartlander and colleagues, on behalf of the Investment Framework Study Group, "propose a strategic investment framework that is intended to support better management of national and international HIV/AIDS responses than exists with the present system" in this Lancet article.
Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.
› Verified 5 days ago
Dr. Rabun Wiley Neves, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1260 S Milledge Ave, Suite F-1, Athens, GA 30605 Phone: 706-543-7386 Fax: 706-543-8544 | |
Dr. Amber Watts, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 221 E Berkeshire Ct, Athens, GA 30606 Phone: 828-612-6231 | |
Thomas Eades, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2301 College Station Rd, Athens, GA 30605 Phone: 706-353-6882 Fax: 706-357-5459 | |
Yvonne H Almond, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4365 Atlanta Hwy, Athens, GA 30606 Phone: 706-548-1913 Fax: 706-548-2481 | |
Mrs. Erin Innman, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1850 Barnett Shoals Rd, Athens, GA 30605 Phone: 706-549-3820 | |
Norma Shiver Young, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2435 Jefferson Rd, Athens, GA 30607 Phone: 706-549-8598 Fax: 706-353-0689 |